Emicizumab

INN name:	For more details visit: http://drugspider.com Emicizumab
Chemical name:	Immunoglobulin G4-kappa, bispecific, anti-[Homo sapiens F9a (activated coagulation factor F9, activated coagulation factor IX) and anti-[Homo sapiens F10 (coagulation factor 10, coagulation factor X)], humanized monoclonal antibody; gamma4 heavy chain (1-448) [humanized VH (Homo sapiens IGHV3-23*04 (87.80%) -(IGHD)-IGHJ4*01 (1- 123)), IGHG4*01 (CH1 K100>Q (202) (124-221), hinge S10>P (231) (222-233), CH2 F84.3>Y (299) (234-343), CH3 E12>K (359), R88>K (412), H115>R (438), L125>P (448) (344-448), CHS>del) (124-448)], (137-214')-disulfide with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; gamma4 heavy chain (1-444) [VH (Homo sapiens IGHV1- 2*02 (75.50%) -(IGHD)-IGHJ6*03 Q120>E (111''), T123>L (114'') (1''-119'')), IGHG4*01 (CH1 A100>Q (198'') (120''- 217''), hinge S10>P (227'') (218''-229''), CH2 F84.3>Y (295''), (230''-339''), CH3 R88>K (408), K119>E (438), L125>P (444) (340''-444''), CHS>del) (120''-444'')], (133''- 214''')-disulfide with kappa light chain (1'''-214''') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9] (1'''-107''') -Homo sapiens IGKC*01, Km3 (108'''-214''')]; dimer (229-225":232-228")- bisdisulfide
Alternate Name:	Immunoglobulin G4-kappa, bispecific, anti-(homo sapiens F9a (activated coagulation factor F9, activated coagulation factor IX) and anti-(homo sapiens F10 (coagulation factor 10, coagulation factor X)), humanized monoclonal antibody Heavy chain anti-F9a QVQLVESGGG LVQPGGSLRL SCAASGFTFS YYDIQWVRQA PGKGLEWVSS 50 ISPSGQSTYY RREVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARRT 100 GREYGGGWYF DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150 LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200 TQTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP 250 KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQYN 300 STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ 350 VYTLPPSQKE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400 LDSDGSFFLY SKLTVDKSRW QEGNVFSCSV MHEALHNRYT QKSLSLSP 448 Heavy chain anti-F10 QVQLVQSGSE LKKPGASVKV SCKASGYTFT DNNMDWVRQA PGQGLEWMGD50 INTRSGGSIY NEEFQDRVIM TVDKSTDTAY MELSSLRSED TATYHCARRK 100 SYGYYLDEWG EGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200 TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF LFPPKPKDTL 250 MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQYNSTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350 PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400 GSFFLYSKLT VDKSRWQEGN VFSCSVMHEA LHNHYTQESL SLSP 444 Light chain DIQMTQSPSS LSASVGDRVT ITCKASRNIE RQLAWYQQKP GQAPELLIYQ 50 ASRKESGVPD RFSGSRYGTD FTLTISSLQP EDIATYYCQQ YSDPPLTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC About drugspider: Drugspider provides, freely, experts verified pipeline/marketed drugs data. The data includes INN/USAN name, brand name, lab code, chemical name, company, clinical trials, ATC codes etc. The intention of drugspider is to help analysts and companies with quickly accessible, trustworthy data of drugs..

Alalevonadifloxacin

INN name:	Alalevonadifloxacin
Lab codes:	WCK-2349
Chemical name:	(5S)-8-[4-(L-alanyloxy)piperidin-1-yl]-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid
Molecular formula:	C22H26FN3O5
Chemical Structure:
CAS Registry Number:	706809-20-3
Originator:	Wockhardt

Acebilustat

INN name:	Acebilustat
Lab codes:	CTX-4430
Chemical name:	4-{[(1S,4S)-5-({4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl}methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl}benzoic acid
Molecular formula:	C29H27N3O4
Chemical Structure:
CAS Registry Number:	943764-99-6
Originator:	Celtaxsys

Evenamide

INN name:	Evenamide
Lab Code(s):	find at Drugspider
Chemical name:	2-{[2-(3-Butoxyphenyl)ethyl]amino}-N,N-dimethylacetamide
Chemical structure:
Molecular formula:	C16H26N2O2
CAS registry number:	1092977-61-1
Originator:	Newron Pharmaceuticals
Class:	Antidepressants Antiepileptic drugs Antimanics Antipsychotics Non-opioid analgesics
Mechanism of action:	Nav1.3 voltage-gated sodium channel inhibitors Nav1.7-voltage-gated-sodium-channel-inhibitors Nav1.8 voltage-gated sodium channel inhibitors
WHO ATC code(s):	N02 (Analgesics) N03A (Antiepileptics) N05A (Antipsychotics) N05B (Anxiolytics) N07X (Other Nervous System Drugs)
EPhMRA code(s):	N2 (Analgesics) N3 (Anti-Epileptics) N5A (Antipsychotics) N5B (Hypnotics/Sedatives) N6A (Anti-Depressants and Mood Stabilisers) N7X (All other CNS drugs)
Clinical trial(s):	Conditions Phases Interventions Status Safety and Tolerability in Healthy Volunteers Phase 1 Drug: NW-3509a Completed

Etripamil

INN name:	Etripamil
Lab codes:	find at Durgspider
Chemical name:	methyl 3-(2-{[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)- 5-methylhexyl](methyl)amino}ethyl)benzoate
Molecular formula:	C27H36N2O4
Chemical Structure:
CAS Registry Number:	1593673-23-4
Originator:	Milestone Pharmaceuticals
Class:	Antiarrhythmics
Mechanism of Action:	Calcium channel antagonists
WHO ATC code:	C01 (Cardiac Therapy) C01B (Antiarrhythmics, Class I and III)
EPhMRA code:	C1 (Cardiac Therapy) C1B (Anti-Arrhythmics)
Clinical Trials: Conditions Phases Status Paroxysmal Supraventricular Tachycardia (PSVT) Phase 2 Recruiting
Recent activities on the drug:

Guadecitabine

INN name:	Guadecitabine
Lab codes:	Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; S-110; SGI-110
Chemical name:	2'-deoxy-5-azacytidylyl-(3'→5')-2'-deoxyguanosine
Molecular formula:	C18H24N9O10P
Chemical Structure:
CAS Registry Number:	929901-49-5
Originator:	SuperGen
Developer:	Astex Pharmaceuticals; Groupe Francophone des Myelodysplasies
Class:	Antineoplastics
Mechanism of Action:	Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
WHO ATC code:	L01B (Antimetabolites)
EPhMRA code:	L1B (Antimetabolites)
Clinical Trials: Conditions Phases Status Leukemia, Myeloid, Acute Phase 3 Recruiting Non-small Cell Lung Cancer Phase 2 Completed MDS Phase 2 Recruiting Hepatocellular Carcinoma Phase 2 Active, not recruiting Previously Treated Metastatic Colorectal Cancer Phase 1 / Phase 2 Recruiting MDS;   CMML;   AML Phase 1 / Phase 2 Active, not recruiting Ovarian Cancer Phase 1 / Phase 2 Active, not recruiting Germ Cell Tumor Phase 1 Recruiting Metastatic Colorectal Cancer Phase 1 Recruiting Acute Myeloid Leukemia Phase 1 Recruiting
Recent activities on the drug:

Motolimod

INN name:	Motolimod
Lab codes:	VTX-2337
Chemical name:	2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
Molecular formula:	C28H34N4O2
Chemical Structure:
CAS Registry Number:	926927-61-9
Originator:	Array BioPharma
Developer:	VentiRx Pharmaceuticals
Class:	Antineoplastics, immunomodulator
Mechanism of Action:	Toll-like receptor 8 (TLR8) agonist
WHO ATC code:	L03A-X
EPhMRA code:	L3A9
Clinical Trials: Conditions Phases Interventions Recruitment Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Phase 2 Combination Active, not recruiting Carcinoma, Squamous Cell of Head and Neck Phase 2 Combination Active, not recruiting Ovarian Cancer Phase 1|Phase 2 Combination Not yet recruiting Low Grade B Cell Lymphoma Phase 1|Phase 2 Combination Terminated  Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Phase 1 Combination Completed Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Phase 1 Combination Completed Squamous Cell Carcinoma of the Head and Neck Phase 1 Combination Recruiting Advanced Solid Tumors|Lymphoma Phase 1 Alone Completed